金斯瑞生物科技(01548.HK)旗下傳奇開曼發行優先股引入多名投資者
金斯瑞生物科技(01548.HK)公布,非全資附屬公司傳奇開曼於2020年3月31日(交易時段前)與買方簽訂了購買協議,據此,傳奇開曼同意向買方發行總計1,930.83股A類優先股,支付對價總額約為1.51億美元,購買價格為每股7.792美元。
買方包括資產管理公司HBC、Johnson & Johnson、生命科學投資公司LAV、投資管理公司Capital Research and Management Company、醫療投資公司Vivo Capital及投資管理公司RA Capital Management。
傳奇開曼計劃將購買事項的所得款項淨額用於營運資金,主要用於研發管線的研究、開發和商業化,擴大生產設施,強化研發平台,以及一般性公司營運支出。
在完成前,公司擁有傳奇開曼84.8%的股份。完成後,公司持有傳奇開曼77.4%的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.